MoneyBall Medicine-logo

MoneyBall Medicine

Health & Wellness Podcasts >

At MoneyBall Medicine, host Harry Glorikian talks with leaders in the healthcare and life sciences industry about the ongoing data-driven transformation of their industry. Having the right data and knowing how to use it will be the key to success in the healthcare market in the future. In drug development and precision medicine, better data is giving physicians new way to diagnose and treat patients. In hospital management and insurance, administrators and information technology directors are using data to bring down costs and create new value. In the world of devices, data and the AI algorithms that act on it are helping doctors do their jobs faster and with more accuracy. Following up on his 2017 book MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market, Harry turns to doctors, hospital administrators, IT directors, entrepreneurs, and others for help mapping out the changes taking place and gauging their impact on everyone from patients to researchers. Welcome to MoneyBall Medicine!

At MoneyBall Medicine, host Harry Glorikian talks with leaders in the healthcare and life sciences industry about the ongoing data-driven transformation of their industry. Having the right data and knowing how to use it will be the key to success in the healthcare market in the future. In drug development and precision medicine, better data is giving physicians new way to diagnose and treat patients. In hospital management and insurance, administrators and information technology directors are using data to bring down costs and create new value. In the world of devices, data and the AI algorithms that act on it are helping doctors do their jobs faster and with more accuracy. Following up on his 2017 book MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market, Harry turns to doctors, hospital administrators, IT directors, entrepreneurs, and others for help mapping out the changes taking place and gauging their impact on everyone from patients to researchers. Welcome to MoneyBall Medicine!
More Information

Location:

United States

Description:

At MoneyBall Medicine, host Harry Glorikian talks with leaders in the healthcare and life sciences industry about the ongoing data-driven transformation of their industry. Having the right data and knowing how to use it will be the key to success in the healthcare market in the future. In drug development and precision medicine, better data is giving physicians new way to diagnose and treat patients. In hospital management and insurance, administrators and information technology directors are using data to bring down costs and create new value. In the world of devices, data and the AI algorithms that act on it are helping doctors do their jobs faster and with more accuracy. Following up on his 2017 book MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market, Harry turns to doctors, hospital administrators, IT directors, entrepreneurs, and others for help mapping out the changes taking place and gauging their impact on everyone from patients to researchers. Welcome to MoneyBall Medicine!

Twitter:

@hglorikian

Language:

English

Contact:

617-407-5093


Episodes

Sandy Aronson on AI and Gene-based Personalized Medicine (AI World Special Series Part 2)

2/15/2019
More
Harry's guest Sandy Aronson argues that AI and apps are not the solution for better healthcare; more effective care workflows enabled by AI and apps are the solution. Aronson is the executive director of information technology at Partners HealthCare Personalized Medicine, and his team develops the IT infrastructure needed to support gene-based personalized medicine in both patient-based and laboratory settings. This episode is the second in a two-part series on getting AI, machine learning,...

Duration:00:41:48

Aalpen Patel and Using AI to Reduce Time-to-Diagnosis (AI World Special Series Part 1)

2/15/2019
More
What if we could use machine learning to train software to read CT scans of patients with intracranial hemorrhaging? Time to diagnosis could be doubled, potentially saving lives. This week Harry discusses such questions with Dr. Aalpen Patel, a physician-engineer who chairs Geisinger's department of radiology and directs is 3D imaging and printing laboratory. This episode is the first in a two-part series on getting AI, machine learning, and analytics working in the healthcare provider...

Duration:00:34:36

Massimo Buscema on AI and What We Can and Can't See in the Human Body

2/1/2019
More
Harry's guest in this episode is Massimo Buscema, director of the Semeion Research Center in Rome, Italy, and a full professor at the University of Colorado at Denver. Buscema researches and consults internationally on the theory and applications of AI, artificial neural networks, and evolutionary algorithms. The conversation focuses on AI and its applications in healthcare, and how it can enhance what we can see and uncover what we cannot.

Duration:00:37:00

Barrett Rollins and the DNA-driven Transformation of Oncology

1/18/2019
More
Harry's guest for this episode is Dr. Barrett Rollins, the chief scientific officer and faculty dean for academic affairs at Boston's Dana Farber Cancer Institute and the Linde Family Professor of Medicine at Harvard Medical School. Harry and Dr. Rollins dig into how large-scale DNA analysis can one day put much more usable information into the hands of oncologists, and how that data affects individual patients, the practice of medicine, and new therapies under development.

Duration:00:30:08

Joel Dudley and What Happens When You Let Data--Not Hypotheses--Drive Discovery

1/4/2019
More
Harry's guest this week is Dr. Joel Dudley from the Icahn School of Medicine at Mount Sinai, where he serves as executive vice president of precision health, associate professor of genetics and genomic sciences, and founding director of the Institute for Next Generation Healthcare. Dr. Dudley explains how his group is utilizing data to uncover health problems that can't be detected through normal methods, as well as his groundbreaking paper on the link between Alzheimer's disease and herpes.

Duration:00:29:00

Wim Van Hecke on Using AI to Quantify Changes in the Brain

12/18/2018
More
Harry talks with Wim Van Hecke, the founder and CEO of Icometrix—builder of a cloud-based AI platform for analyzing brain MRI and CT scans—to find out how the startup's FDA-cleared technology is changing the way radiologists and other physicians interpret neuroimaging data.

Duration:00:32:41

Robert Green on the Impact of Individual Genomic Data

12/7/2018
More
Harry's guest this week, Dr. Robert Green, is a professor of medicine and genetics at Harvard Medical School and director of the Genomes To People research program at Brigham & Women's Hospital and the Broad Institute of Harvard and MIT. They dig into the individual genome, how genomic data is being used, and the impact of genomics on various stakeholders in the healthcare system.

Duration:00:37:07

Sharon Terry on Changes in Drug Discovery, Diagnostics, and the Treatment of Patients

11/23/2018
More
Harry talks with Sharon Terry, president and CEO of Genetic Alliance, about the way drug discovery, diagnostics , and the treatment of patience are changing.

Duration:00:33:47

Fabien Beckers on AI and the Future of Medical Imaging

11/16/2018
More
Today's radiologists face a deluge of data, and their work can be tedious and error-prone. But should humans even act as radiologists? It's becoming clear that computers and humans working together are better than either alone. Harry's guest this week is Fabien Beckers, CEO of Arterys, a startup creating products at the intersection of AI, the cloud, and medical imaging.

Duration:00:28:34

Wout Brusselaers: Every Patient in a Clinical Trial: How AI Can Solve One of Healthcare's Biggest (and Most Expensive) Problems (AI Biopharma Special Series Part 6)

11/14/2018
More
Harry speaks with Wout Brusselaers, CEO and founder of Deep6.AI, about new technology that could help find patients for clinical trials in minutes rather than months. This is Part 6 of a six-part special series recorded at the AI Applications Summit, produced in Boston by Corey Lane Partners in October 2018.

Duration:00:32:46

Guido Lanza: Can AI Prevent Failure in Drug Discovery Pipelines? (AI Biopharma Special Series Episode 5)

11/14/2018
More
Harry's guest is Guido Lanza, president and CEO of Numerate. They tackle the question: What if the introduction of AI into drug discovery allowed us to create a true learning loop? This is Part 5 of a special six-part series recorded at the AI Applications Summit, produced in Boston by Corey Lane Partners in October 2018.

Duration:00:39:11

Ron Alfa: To Reimagine Drug Discovery & Development, Let the Data Drive the Process (AI Biopharma Special Series Part 4)

11/14/2018
More
Harry asks Dr. Ron Alfa, vice president of discovery and product at Recursion Pharmaceuticals, what efficiencies could be achieved and what problems could be solved if data science were applied to drug discovery. This is Part 4 of a special six-part series recorded at the AI Applications Summit, produced in Boston by Corey Lane Partners in October 2018.

Duration:00:16:50

Shrujal Baxi: Is AI Ready to Solve Healthcare's Real-World Evidence Problem? (AI Biopharma Special Series Part 3)

11/14/2018
More
Harry's guest is Dr. Shrujal Baxi, medical director of Flatiron Health. On the agenda: how technology can help create the real-world evidence needed to achieve better patient outcomes and accelerate research into new areas. This is Part 3 of a 6-part special series recorded at the AI Applications Summit, produced in Boston by Corey Lane Partners in October 2018.

Duration:00:23:17

Milind Kamkolkar: Big Pharma is Paying Attention, But Can They Adapt to the AI-Driven Landscape? (AI Biopharma Special Series Part 2)

11/14/2018
More
In this episode Harry talks with Milind Kamkolkar, chief data officer at Sanofi, about how big pharma can start using new data sources to uncover new insights about disease. This is Part 2 of a special 6-part series recorded at the AI Applications Summit produced in Boston by Corey Lane Partners in October 2018.

Duration:00:31:11

Andrew A. Radin: From Validation to Pharma Pipeline—How AI is Finding the Patterns in Data (AI Biopharma Special Series Part 1)

11/14/2018
More
Harry interviews Andrew A. Radin, co-founder and CEO of twoXAR, an AI-driven drug discovery startup that unifies disparate data to identify potential disease treatments. This episode is Part 1 of a 6-part special series recorded at the AI Applications Summit produced in Boston by Corey Lane partners in October 2018.

Duration:00:23:57

Leah Binder on How Price and Quality Transparency Helps Patients and Employers

11/9/2018
More
Leapfrog Group president and CEO Leah Binder talks with Harry about data transparency and how it helps inform healthcare decisions by putting the right information in the hands of patients and employers.

Duration:00:39:11

John Glaser and How AI is Affecting Electronic Medical Records Systems

10/26/2018
More
Harry's guest John Glaser, senior vice president of population health at Cerner, speculates on how business models in healthcare are changing and how artificial intelligence and EMR systems will work together in the future.

Duration:00:34:15

Dekel Gelbman and How Machine Learning Is Changing Rare Disease Diagnosis

10/12/2018
More
Harry's guest is Dekel Gelbman, founding CEO of FDNA. The company uses a combination of computer vision, deep learning, and other artificial intelligence techniques to improve and accelerate diagnostics and therapeutics for children with rare diseases.

Duration:00:38:09

Jason Bahn and How AI and Machine Learning Are Enabling Early Disease Detection

10/1/2018
More
Jason Bahn, co-founder and chief medical officer of Prognos, joins Harry to talk about how machine learning is being used to dig into multi-sourced clinical diagnostic data to improve health by predicting disease early.

Duration:00:31:22

Niven Narain and How AI and Machine Learning Are Changing Drug Discovery

9/15/2018
More
Harry interviews Niven Narain, the co-founder, president and CEO of Berg, a Boston-based biopharma company driving the next generation of drugs and diagnostics by combining patient-driven biology and AI to unravel actionable disease insight. Narain has overseen development of Berg’s clinical stage assets and pipeline and forged strategic partnerships with industry academic and US and UK governments. He says Berg's philosophy is to combine a systems biology architecture with patients'...

Duration:00:39:04